

THW

CASE ON/4-32744A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EXPLOS Mail Label Number

949457 23, 200 G

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

JOSEPH ALEXANDER LASKY

INTERNATIONAL APPLICATION NO: PCT/IB03/04671

FILED: 20 OCTOBER 2003

U.S. APPLICATION NO: 10/532,297

35 USC §371 DATE: 24 AUGUST 2005

FOR: USE OF N-{5-[4-(4-METHYLPIPERAZIOMETHYL)-

BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY

HYPERTENSION

MS: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed June 22, 2006. Since Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449.

A copy of this reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7852

Date:

August 23, 2006

Respectfully submitted,

Oona A. Jackson Attorney for Applicant Reg. No. 48,152 FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32744A
APPLICATION NO.
10/532,297
APPLICANT
Joseph Alexander Lasky
FILING DATE
AUGUST 24, 2005

Group 1614

AUG 2 3 2006 gg

א אוועס און צ									
3 ZUUD EU			U.S. I	PATENT DOCUMENTS					
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE	
	AA								
	AB								
	AC						\top		
	AD								
	AE						1		
	AF								
	AG								
	АН								
	AI								
	AJ						1		
	AK								
	AL		· · · · · · · · · · · · · · · · · · ·						
	•	•	FOREIG	N PATENT DOCUMENTS			a	• • • • • • • • • • • • • • • • • • • •	
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	ISLATION NO	
	AM								
	AN								
	AO								
	AP								
	AQ				-				
		OTHER DOC	UMENTS (Including Author, Title, Date, Perti	nent pages, E	itc.)		-	
·	AR	Ghofrani et al., "Imatinib for the Treatment of Pulmonary Arterial Hypertension," The New England Journal of Medicine, Vol. 353, No. 13, p. 1412-1413 (2005)							
	AS								
	АТ				<u>.</u>				

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED